News | Cardiovascular Ultrasound | September 14, 2021

FDA Clears Fully Automated Cardiac Ultrasound Solution to Measure 2D and Doppler

The Us2.ai artificial intelligence received external validation at Brigham and Women's Hospital of Harvard Medical School

Us2.ai has received U.S. Food and Drug Administration (FDA) clearance for its artificial intelligence (AI) Us2.v1 software, a completely automated decision support tool for echocardiography.

September 14, 2021 – Us2.ai, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S. Food and Drug Administration (FDA) clearance for Us2.v1, a completely automated decision support tool for echocardiography.

After multiple trials with global pharmaceutical partners, and a validation study at the Brigham & Women’s Hospital, Us2.ai announced the artificial intelligence (AI) software is now available for clinical use in the United States. 

Us2.v1 is an automated clinical workflow solution that recognizes and analyzes 2-dimensional and Doppler echo images for comprehensive cardiac ultrasound measurements needed for the diagnosis, prediction and prognosis of heart disease.

"With this release, we’ve moved the field of AI beyond just a narrow feature for echocardiography, to a complete decision-support solution for cardiologists and primary care providers,” said James Hare, CEO and co-founder of Us2.ai. “Us2.v1 eliminates the manual workflows and lack of transparency from semi-automated, single measurement, black box AI approaches, creating a complete and fully automated patient report with editable annotations, conclusions and comparisons to international reference guidelines.”

Us2.v1 automated measurements include 2-D (cardiac volumes, all 4 chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler; thus covering the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography (ASE), European Association of Cardiovascular Imaging, and British Society of Echocardiography.  

Fully automated Us2.v1 measurements were shown to be completely interchangeable with expert human measurements. The AI measurements also were completely reproducible for a given patient study, with image processing/analysis algorithm computation time of approximately 2 minutes per study, the vendor said.

Us2.v1 is designed to help to accelerate the diagnosis of diseases such as pulmonary hypertension and heart failure (HF). 

The company recently announced a partnership with EchoNous, maker of ultra-portable, AI-guided, point-of-care ultrasound (POCUS) tools. EchoNous is the maker of Kosmos, the only handheld ultra-mobile tool offering diagnostic grade imaging with Continuous-Wave (CW) Doppler capability.

Us2.v1 also automates the detection of pulmonary hypertension according to the European Society of Cardiology (ESC) / European Respiratory Society (ERS) guideline definition for echocardiographic detection of pulmonary hypertension. Pulmonary hypertension remains under-detected, leading to treatment delays and poor outcomes. 

Similarly, heart failure is a commonly missed diagnosis, particularly in general practices where access to echocardiography is currently limited. 

“AstraZeneca is excited to partner with Us2.ai because we believe it has the potential to transform the management of heart failure, bringing early access to echocardiography, including expert-level analyses, to primary care settings, the general community and even to patients’ home. Together, we look forward to helping improve care for patients with heart failure and keeping them out of hospital”, said Joris Silon, senior vice president, CVRM, bioPharmaceuticals business unit, AstraZeneca.

For more information: https://us2.ai/

Find more artificial intelligenece in cardiology content

Find more new cardiac ultrasound technology content

Related Content

News | Artificial Intelligence

August 18, 2022 — Six digital healthcare start-ups from five countries have officially become the first cohort of the ...

Home August 18, 2022
Home
News | Artificial Intelligence

August 16, 2022 — Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis ...

Home August 16, 2022
Home
News | Artificial Intelligence

August 11, 2022 — The recent deals and collaborations in the medical device space indicate a growing interest in ...

Home August 11, 2022
Home
News | Artificial Intelligence

July 25, 2022 — Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their ...

Home July 25, 2022
Home
News | Artificial Intelligence

July 19, 2022 — Employing artificial intelligence to help improve outcomes for people with cardiovascular disease is the ...

Home July 19, 2022
Home
News | Artificial Intelligence

July 14, 2022 — Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a ...

Home July 14, 2022
Home
News | Artificial Intelligence

July 7, 2022 — Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American ...

Home July 07, 2022
Home
News | Artificial Intelligence

June 8, 2022 — Us2.ai, a Singapore-based medtech firm backed by, IHH Healthcare, Heal Partners, Sequoia India, EDBI ...

Home June 08, 2022
Home
News | Artificial Intelligence

June 7, 2022 — ScImage Inc., a leading provider of enterprise imaging solutions and DiA Imaging Analysis, a global ...

Home June 07, 2022
Home
News | Artificial Intelligence

May 26, 2022 — At the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health ...

Home May 26, 2022
Home
Subscribe Now